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A b s t r a c t  
The objective of the research investigation was to design and evaluate the oral once a day matrix 
tablets of valsartan by using various natural matrix former gums such as separately. Initially natural 
gums are extracted and purified and their extracts are evaluated for their proximate phyto-chemical 
studies. Tablets were prepared by wet granulation method. The prepared tablets were further 
evaluated for physical parameters, In-vitro dissolution, and drug-excipients interactions are also 
carried out. The FT-IR studies revealed that there was no chemical interaction between drug and 
excipients. Among all prepared formulations, formulation F-8 exhibited precise controlled release of 
drug over a prolonged period of 24 hrs. The in- vitro dissolution data obtained for various 
formulations were fitted into zero order, first order, Higuchi’s and Korsymeyer - Peppas kinetic 
models. The optimized formulation displayed zero order release kinetics and Korsmeyer and Peppas 
equation give release pattern with values of (n = 0.9094) indicating non-fickian (or) Anomalous types 
of diffusion takes place through matrix of Gum Kondagogu. The optimized formulations F-8 was 
subjected to stability studies for three months at  400C/75%RH as per ICH guidelines and result 
does not shows any change in physical parameters and in-vitro release studies.  
Keywords: valsartan; FT-IR studies; Caco-2; permeability; absorption enhancement 
Introduction 
Most conventional oral drug products, such as tablets and 
capsules, are formulated to release the active drug immediately 
after oral administration, to obtain rapid and complete systemic 
drug absorption. Such immediate-release products result in 
relatively complete systemic drug absorption and onset of 
accompanying pharmacodyanmic effects. However, after 
absorption of the drug from the dosage form is complete, plasma 
drug concentration decline according to the drug’s pharmacokinetic 
profile [1]. Eventually, plasma drug concentrations fall below the 
minimum effective plasma concentration (MEC), resulting in loss of 
therapeutic activity. Before this point is reached, another dose is 
usually given if a sustained therapeutic effect is desired. An 
alternative to administering another dose is to use a dosage from 
that will provide sustained drug release, and therefore maintain 
plasma drug concentrations, beyond what is typically seen using 
immediate-release dosage forms. In recent years, various modified-
release drug products have been developed to control the release 
rate of the drug and / (or) the time for drug release [2]. 
 
Types of Modified Release Drug Products 
 
Several types of modified –release drug products are recognized 
[4]. 
Extended-Release Drug Products:  A dosage form that allows at 
least a twofold reduction in dosage frequency as compared to that 
drug presented as an immediate-release (conventional) dosage 
form. Examples of extended-release dosage forms include 
controlled-release, sustained-release, and long acting drug 
products. 
Delayed-Release Drug Products:  A dosage form that releases a 
discrete portion or portions of drug at a time (or) at times other than 
promptly after administration, although one portion may be 
released promptly after administration. Enteric-coated dosage 
forms are the most common delayed-release products. 
Targeted-Release Drug Products: A dosage forms that release 
drug at or near the intended physiologic site of action. Targeted-
release dosage forms may either immediate (or) extended- release 
characteristics. 
The term controlled-release drug product was previously used to 
describe various types of oral extended-release-rate dosage forms, 
including sustained-release, sustained action, long-action, slow-
release, and programmed drug delivery. 
 
Matrix Tablets 
 
One of the least complicated approaches to the manufacture of 
controlled release dosage forms involves the direct compression of 
blend of drug, retardant material and additives to formulate a tablet 
in which the drug is embedded in a matrix of the retardant. 
Alternatively drug and retardant blend may be granulated prior to 
compression. Matrix tablets is a promising approach for the 
establishment of extended release drug therapy as tablets offer the 
lowest cost approach to sustained and controlled release and 
sustained release solid dosage forms[20] 
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Matrix tablets may be defined as the “oral solid dosage forms in 
which the drug (or) active ingredient is homogeneously dispersed 
throughout the hydrophilic (or) hydrophobic matrices which serves 
as release rate retardants [21]. These systems release drug in 
continuous manner by dissolution-controlled and diffusion-
controlled mechanisms. Under gastric pH conditions, matrix tablet 
slowly erodes. However at a pH corresponding to the upper small 
intestine, the tablet disintegrates rapidly to reduce coated particles, 
which in turn slowly releases drug. Two different release 
mechanisms are operative, either of which is zero order erosion 
and decreasing surface area, and dissolution of coated particles, 
but the overall tablet release profile comprising the two 
mechanisms in sequence is nearly linear for most of the dose in the 
tablet. The result in the ability to control active pharmaceutical 
ingredient’s blood level’s in a narrow range, above the minimum 
effective level and below toxic level [22]. 
 
Materials 
 
Valsartan was gift sample from Spectrum Pharma Labs Hyd. Gum 
Olibanum (Grade I), Gum Kondagugu (Grade I) were obtained as 
gift sample from Andhra Pradesh Girijan Society. Locust Bean Gum  
was gift sample from Balaji Drugs Limited HYD. 
 
Methodology 
Method of preparation of Valsartan Matrix Tablets 
All the matrix tablets, each containing 80 mg of valsartan, were 
prepared by wet granulation method. 
All the ingredients of the formulation were passed through sieve 
no# 60 and were blended in a mortar with a pestle to obtain uniform 
mixing.  
 
Wet granulation  
 
Matrix tablets of valsartan are prepared as per the formulae given 
in table.  
The required quantities of Drug and the Micro crystalline Cellulose 
(diluents), PVP K-30 were sifted through sieve# 40 manually and 
mixed well in a mortar by following geometric dilutions to ensure 
the uniformity of premix blend.  
The granulating fluid was added and mixed thoroughly to form 
dough mass. 
The mass was passed through sieve #20 and Sieve #16 to obtain 
wet granules. 
The wet granules were dried at 45°C ± 5°C for 1 hour in a hot-air 
oven and the dried granules were sieved through sieve #10, #12, 
#14, #16, #20 to break aggregates. 
The glidant talc and lubricant magnesium stearate were passed 
through sieve #100 on to dry granules and were blended in a 
closed polyethylene bag. 
The tablet granules were compressed into tablets on an 8 station 
rotary tablet punching machine equipped with flat-faced, round 
punches of 8-mm diameter to a hardness of 6-7 kg/cm2. ‘’ 
  
Table 1: Composition of Matrix Tablets 
S.No Ingredient (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1. Valsartan 80 80 80 80 80 80 80 80 80 80 80 80 
2. Gum Olibanum Resin 4 6 8 10 - - - - - - - - 
3. Purified Gum Kondagugu - - - - 30 40 50 60 - - - - 
4. Locust Bean Gum - - - - - - - - 30 40 50 60 
5. 
Poly Vinyl Pyrrolidine K-
30 
20 20 20 20 20 20 20 20 20 20 20 20 
6. 
Micro Crystalline 
Cellulose 
(Avicel pH 101) 
86 84 82 80 60 50 40 30 60 50 40 30 
7. Magenisum Stearate 5 5 5 5 5 5 5 5 5 5 5 5 
8. Talc 5 5 5 5 5 5 5 5 5 5 5 5 
9. * Ethyl alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
10. Total weight of the Tablet 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
200 
mg 
*Q.S = Quantity Sufficient. 
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Results and Discussion 
 
Authentification of Drug Sample and Drug-Excipient Interaction Study by FTIR Analysis 
 
 
 
 
 
.  
Figure 1 FTIR Spectra of ---   a- Valsartan Drug Sample, b- Purified Valsartan and Gum Olibanum Resin Mixture,                                                
c- Purified Valsartan and Purified Gum Kondagogu Mixture, d- Purified Valsartan and Purified Locust Bean Gum Mixture 
 
IR spectral studies revealed that the positions of the characteristic 
absorption bands for different functional groups and bonds of the 
pure drug were not changed considerably indicating that no 
interactions of the drug with polymers and others excipients used 
for the study.  
Interpretation of FTIR Spectrum of Drug Sample and 
Drug-Polymer Mixtures 
 
 
a 
b 
c 
d 
Kumar et. al. International Journal of Drug Delivery 7 (4) 208-222 [2015] 
 
 
  
PAGE | 211 | 
 
 
Table 2: Interpretation of IR Data 
 
 
 
 
 
 
Determination of Melting Point 
 
 
 
Table 3: Melting Point of Valsartan 
 
No. of Trails 
Melting Point ( 0C) 
Observed Melting Point ( 
0C) 
Average  Melting Point ( 
0C) 
Reference Melting Point ( 
0C) 
Trail 1 116  
116 
 
116-118 Trail 2 118 
Trail 3 116 
       
 
Evaluation Tests 
 
Evaluation of Micrometric Properties of Formulated Granules 
S.No. 
Functional 
Group 
Present 
Type of Vibrations Reference Peak  
(cm-1) 
Observed Peak (cm-1) 
Valsartan 
Pure 
Valsartan 
and Gum 
Olibanum 
Resin 
Mixture 
Valsartan 
and Purified 
Gum 
Kondagogu 
Mixture 
Valsartan 
and Locust 
Bean Gum 
Mixture 
1. Aliphatic 
CH Stretching 2850 - 3000 2962.76 2951.19 2964.69 2962.76 
CH Bending 1378 - 1467 1456.3 1448.59 1456.3 1456.3 
2. Aromatic CH Stretching 3000 - 3100 3030.13 2974.33 3030.27 3032.2 
3. Carboxylic 
acid 
C=O Stretching 1050 - 1150 1105.25 1107.18 1105.25 1105.25 
4. Aromatic C=C Stretching 1400 - 1600 1471.74 1473.66 1473.66 1471.74 
6. Aliphatic C-N Stretching 1030 - 1230 1203.62 1205.55 1207.48 1203.62 
7. Amide N-H  Stretching 3100 - 3500 3460.41 3462.34 3462.34 3446.91 
8. Amide C=O  Stretching 1680 - 1760 1732.13 1734.06 1732.13 1732.13 
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Table 4: Micrometric Properties of Granules (Pre-compression Data) 
Formulation Codes Angle of Repose (°) 
Bulk Density 
(gm/ml) 
Tapped Density 
(gm/ml) 
Carr's Index (%) Hausner's Ratio 
F1 21.21±0.03 0.44±0.04 0.52±0.06 17.18±0.04 1.22±0.91 
F2 20.28±0.06 0.51±0.05 0.58±0.04 13.79±0.05 1.16±0.93 
F3 22.65±0.05 0.54±0.03 0.61±0.07 15.12±0.03 1.19±0.92 
F4 21.21±0.01 0.43±0.06 0.51±0.05 14.0±0.06 1.16±0.89 
F5 22.68±0.09 0.40±0.05 0.45±0.06 11.11±0.07 1.12±0.93 
F6 23.62±0.07 0.43±0.04 0.52±0.04 17.03±0.05 1.08±0.87 
F7 20.70±0.06 0.47±0.03 0.56±0.07 12.10±0.05 1.11±0.93 
F8 21.24±0.05 0.48±0.06 0.60±0.05 18.09±0.06 1.13±0.91 
F9 22.11±0.04 0.44±0.07 0.52±0.07 15.07±0.07 1.15±0.89 
F10 21.09±0.02 0.42±0.06 0.51±0.05 14.05±0.05 1.17±0.92 
F11 22.34±0.08 0.46±0.09 0.54±.09 12.13±0.04 1.14±0.87 
F12 21.68±0.02 0.44±.07 0.52±0.07 12.34±0.01 1.16±0.91 
*All the values represented as mean ± Standard Deviation (SD), n=3 
 
The Micrometric properties of granules for matrix tablets were 
characterized with respect to angle of repose, bulk density, tapped 
density, Carr's index and Hausner’s ratio (table). Angle of repose ( ) 
was found to be within 20° - 24° and Carr's index values were less 
than 21 for all granules of all formulations indicating good to fair 
flowability and compressibility. Hausner's ratio was found to be less 
than 1.25 for granules of all formulations indicating good flow 
properties. 
 
Post-Compression Evaluation Tests 
 
Physical appearance: Tablets were white in color with good texture.  
Plane on one side and Debussed on other side. 
The results of the weight variation, hardness, thickness, friability 
and drug content of the prepared matrix tablets of valsartan are 
given in table 5.  
All the tablets of prepared formulations are compiled with the 
official requirements of weight variation as per I.P and U.S.P as 
their weights varied in between 200–203 mg. 
The hardness of the tablets ranged from 6-7 kg/cm2 and the 
friability values were found to be less than 0.8% indicating the 
matrix tablets were compact and hard thus they can withstand 
mechanical hazards. 
The thicknesses of the tablets were ranged from 2.90-3.40 mm. 
All the formulations satisfied the content of the drug as they 
contained 90-100 % of variation and good uniformity in drug 
content was observed        
 
Table 5: Physical Evaluation of Matrix Tablets 
 
Formulation Codes 
‡ Weight Variation 
(mg) 
*   Thickness 
(mm) 
*  Hardness  
(kg/cm 2 ) 
Friability 
(%) 
Drug Content 
Uniformity (%) 
F1 200±0.7 3.37±0.25 6.8±0.13 0.39 98.75 
F2 201±0.5 3.14±0.80 6.4±0.15 0.43 98.76 
F3 201±0.6 3.20±0.20 6.6±0.13 0.12 97.99 
F4 200±0.8 3.08±0.66 6.8±0.14 0.54 95.80 
F5 202±0.7 3.33±0.25 6.8±0.16 0.58 90.79 
F6 203±0.6 3.24±0.71 6.4±0.15 0.64 97.90 
F7 203±0.5 3.32±0.89 6.5±0.15 0.37 99.45 
F8 200±0.6 3.38±0.73 6.9±0.14 0.17 99.67 
F9 203±0.7 3.00±0.68 6.4±0.16 0.42 92.08 
F10 200±0.7 2.98±0.88 6.4±0.11 0.48 95.49 
F11 200±0.5 3.11±0.36 6.7±0.15 0.15 97.56 
F12 201±0.6 3.06±0.46 6.6±0.13 0.27 98.11 
* All the values represented as mean ± Standard Deviation (SD), n=3. 
‡ All the values represented as mean ± Standard Deviation (SD), n=20
Kumar 
 
 
 
 Thus all the physical attributes of the prepared matrix tablets
found to be practically within control. 
 
Swelling Index 
 
Since the rate of swelling is related and may affect the mechanism 
and kinetics of drug release, the penetration of the dissolution 
medium and weight gained by hydrated tablets were determined.
 
Table 6: Swelling Index Stud
S.No Formulation Code
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
 
Figure.2: Bar Graph Swelling Index Study of Valsartan Matrix Tablet Formulation
 
 
In vitro Drug Release Studies 
 
Drug Release from Gum Olibanum Resin Matrices 
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The swelling studies were conducted for all formulations i.e., F1 to 
F12. Since, the rate of swelling is related and may affect the 
mechanism and kinetics of the drug release, the penetration of the 
dissolution medium of the matrix tablets was determined.
swelling was observed in formulations containing the gum 
kondagogu (F5-F8) as matrix formers. The swelling index of the 
tablets from each formulation (F1 to F12) was evaluated and the 
results are provided in Table 6. 
y of Valsartan Matrix Tablet Formulation 
 
Initial Wt. Of Tablet  
(Wt) (mg) 
Wt. of Tablet After 
Swollen Time (mg) 
(W0 ) 
F1 200 294.96 
F2 201 341.86 
F3 201 367 
F4 200 375.22 
F5 202 506.4 
F6 203 570.12 
F7 203 610.68 
F8 200 660.78 
F9 203 332.58 
F10 200 349.74 
F11 200 375 
F12 201 389.6 
                   
 
The results of release studies of formulations F1 to F4 are shown in 
Table 7 and Figure. 
The release of drug depends not only on the nature of matrix but 
also upon the drug and polymer ratio. As the percentage of polymer 
increased, the drug release was decreased.
) 208-222 [2015] 
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Thus, this phenomenon may be due to the fact that that as the 
increased density of the polymer matrix at higher concentration 
resulting an increased diffusional path length. There by decreasing 
the overall drug release from the polymer matrix. 
Table 7: In vitro Dissolution Data of valsartan Matrix Tablets of Formulations F1 to F4 
 
S.NO 
 
Time (hrs) 
Percentage Cumulative Drug Release (%CDR) 
F1 F2 F3 F4 
1 0 0 0 0 0 
2 0.25 1.755 1.161 1.224 1.377 
3 0.5 1.890 1.563 1.428 1.609 
4 0.75 2.396 1.869 1.778 1.771 
5 1 3.381 2.266 1.887 1.871 
6 1.5 4.363 2.827 2.563 4.869 
7 2 4.593 3.302 2.712 5.535 
8 3 13.800 15.227 6.024 26.937 
9 4 17.983 18.569 16.339 29.702 
10 5 25.599 25.296 28.051 31.860 
11 6 37.082 30.331 29.3621 38.332 
12 7 40.627 33.873 34.161 40.411 
13 8 43.354 47.549 39.644 45.183 
14 9 47.310 48.836 49.845 48.081 
15 10 54.220 51.343 54.639 51.948 
16 11 62.527 57.868 58.666 55.898 
17 12 70.267 60.594 62.263 60.048 
18 14 75.215 70.434 66.419 62.862 
19 16 77.780 72.758 69.3549 67.363 
20 18 83.853 76.767 76.759 71.635 
21 20 86.879 84.738 80.801 74.778 
22 22 94.302 82.924 84.044 77.990 
23 24 95.248 90.555 86.799 79.723 
      
Drug Release from Purified Gum Kondagogu Matrices 
 
The results of release studies of formulations F5 to F8 are shown in 
Table 8 and Figure 4. 
Hydrophilic gum kondagogu can be used as matrix former as rate 
retarding polymer in formulation of matrix tablets. Formulations 
containing purified gum kondagogu F5 to F8 as release rate 
retardant extended the release up to 22-24hrs. As the polymer 
concentration increased the drug release was. This may be due to 
the mobility of the polymer chains strongly depends on the water 
content of the system. At high water content, polymer chain 
relaxation takes place with volume expansion giving rise to high 
swelling of the system.  
Consequently, faster and higher swelling of the tablet led to 
increase in dimensions of the tablet, leading to increasing the 
diffusion pathways and thus increasing the drug release. 
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Table 8: In vitro Dissolution Data of valsartan Matrix Tablets of Formulations F5 to F8 
 
S.NO 
 
Time (hrs) 
Percentage Cumulative Drug Release (%CDR) 
F5 F6 F7 F8 
1 0 0 0 0 0 
2 0.25 1.404 2.241 3.582 2.187 
3 0.5 2.725 3.072 3.880 2.928 
4 0.75 3.559 3.575 4.343 3.601 
5 1 6.9545 4.279 4.808 4.206 
6 1.5 12.401 6.417 10.657 4.283 
7 2 15.332 9.386 16.080 4.441 
8 3 31.361 14.138 42.909 9.004 
9 4 36.886 18.260 48.0263 9.264 
10 5 47.796 22.944 51.578 14.213 
11 6 52.268 34.755 52.241 16.211 
12 7 54.091 42.653 54.275 24.088 
13 8 54.853 45.725 60.972 26.185 
14 9 56.013 51.342 63.0348 32.622 
15 10 67.249 60.527 66.844 35.846 
16 11 71.455 69.770 68.927 41.732 
17 12 81.721 74.419 76.3664 46.228 
18 14 86.103 80.739 80.8753 49.875 
19 16 89.094 85.526 82.419 55.125 
20 18  88.105 83.412 67.981 
21 20  90.103 85.929 79.593 
22 22   87.883 83.239 
23 24   90.583 96.695 
 
Drug Release from Locust Bean Gum Matrices 
 
The results of release studies of formulations F9 to F12 are shown in Table 9 and Figure 5. 
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Table 9: In vitro Dissolution Data of valsartan Matrix Tablets of Formulations F9 to F12 
 
S.NO 
 
Time (hrs) 
Percentage Cumulative Drug Release (%CDR) 
F9 F10 F11 F12 
1 0 0 0 0 0 
2 0.25 1.473 1.755 1.42 1.179 
3 0.5 3.590 1.890 1.762 1.248 
4 0.75 4.537 2.702 2.357 2.218 
5 1 5.633 2.789 2.883 3.247 
6 1.5 8.337 3.281 3.241 3.742 
7 2 12.585 3.992 4.348 4.915 
8 3 30.342 12.245 9.730 18.127 
9 4 35.445 19.428 19.300 22.826 
10 5 43.186 25.588 27.825 26.984 
11 6 48.295 29.586 33.273 30.787 
12 7 50.742 33.732 40.390 40.298 
13 8 57.232 37.675 42.649 46.738 
14 9 59.276 43.304 45.2706 52.115 
15 10 62.445 48.289 49.54 56.350 
16 11 67.854 56.161 52.974 63.407 
17 12 69.755 57.687 58.367 69.034 
18 14 75.696 61.946 68.586 78.678 
19 16 79.850 65.840 75.269 80.561 
20 18 80.705 68.188 81.339  
21 20 84.515 76.109   
22 22 86.876 81.436   
23 24 90.887 88.391   
 
The results of In vitro dissolution study of matrix tablets were 
prepared from locust bean gum with varying gum concentration in 
formulation F9 to F12 shows drug release was not satisfactory up 
to 24hrs.  
It is reported that as the concentration of gum increase the drug 
release was decreased. This phenomenon may citied as in the 
literature that by increasing the polymer concentration, a viscous 
gel layer is formed, resisting to the erosion and the diffusion of the 
drug is mainly controlled primarily by the gel viscosity.  
The viscosity of the gum solution strongly increases with increase 
in the concentration of gum. The behavior is attributable to the 
intermolecular interaction (or) entanglement, increasing the 
effective macromolecule dimensions and molecular weight. As a 
result of rheology of hydrated product, the swollen particles 
coalesce.   
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Figure 3: comparison of 
Figure 4: comparison of 
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in vitro drug release profile of F5-F8 formulations 
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Figure 5: comparison of 
 
Table 10: Comparison of Kinetic Data of Optimized Formulation F8
Formulation Code Correlation Coefficient (r
 
Zero 
Order 
First Order
F8 0.9877 
                                    
The release rate kinetics data for the F8 is shown in table 10 . As 
shown in figures 6-9, drug release was best explained by Zero
order equation, as the plots showed higher linearity (r2=0.9877), 
followed by Korsmeyer - Peppas (r2=0.9514) and Higuc
(r2=0.894) and first order (r2=0.7948). As the drug release was 
best fitted in the Zero order kinetics, indicating that the rate of drug 
release is concentration independent. 
 
Mechanism of Drug Release 
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2) 
Diffusional 
Exponent (n)
 
Higuchi 
Equation 
Korsmeyer -
Peppas 
Korsmeyer 
Peppas 
0.7948 0.894 0.9514 0.9094 
-
hi equation 
 
As shown in fig.9, the corresponding plot
Release Vs Log time) for Korsmeyer –
good linearity (r2=0.9514). The diffusional exponent “n” was 
0.9094, which appears to indicating the release of drug polymer 
matrix formulations was found to be super ca
drug release by more than one mechanism. Super case II transport 
generally refers to erosion of polymeric chain and anomalous 
transport. 
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Inference 
-
 
Zero order  
and Super 
Case II 
Transport 
 (Log Cumulative Drug 
 Peppas equation indicated a 
se-II transport, i.e., 
Kumar 
 
 
 
Figure.6: Zero order Graph for Kinetic Data of Optimized Formulation F8
 
Figure.7: First order Graph for Kinetic Data of Optimized Formulation F8
Figure.8: Higuchi Equation Kinetic Data of Optimized Formulation F8
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Figure.9: Korsemyer
Accelerated Stability Studies 
 
Stability studies of the optimized formulation did not reveal any degradation of the drug and dosage form.
 
Table 11: Accelerated Stability Study of Optimized Formulation F8
Parameter 
0 Month 
*Hardness (kg/cm2) 6.9±0.14 
Friability (%) 0.17 
*Thickness(mm) 3.38±0.73 
* Drug content (%) 99.67±0.040
In vitro drug release (%) 96.69 
*All the values r
The stability of this optimized formulation was known by performing stability studies for three months at accelerated conditi
optimized formulation. The formulation was found to be stable, with no change in the weight variation, thickness, and friability, hardness, drug content and 
drug release pattern. The results are tabulated in table 11.
 
Table 12: Phytochemical Evaluation of Gum Olibanum Resin
S.No. 
1. Solubility Test in Water
2. Solubility Test in Ether
3. 
4. Hydrochloric Acid Test
5. Ferric Chloride Test
6. Cupric Acetate Test
et. al. International Journal of Drug Delivery 7 (4
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-Peppas Graph for Kinetic Data of Optimized Formulation F8 
 
 
 
Time (Months) 
1st  Month 2nd  Month 
6.9±0.12 6.9±0.10 
0.17 0.17 
3.38±0.65 3.38±0.55 
 99.65±0.039 99.62±0.019 
96.69 96.69 
epresented as mean ± Standard Deviation (SD), n=3. 
 
 
Test Inference 
 Insoluble in Water 
 Soluble in Ether 
Turbidity Test 
Turbidity was observed when added to 
water 
 Pink color was developed upon heating
 Brown to Blue color was observed
 Green color was observed
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3rd  Month 
6.9±0.09 
0.17 
3.38±0.55 
99.62±0.013 
96.69 
ons of 400C + 75 % RH on 
In vitro 
 
 
 
Kumar et. al. International Journal of Drug Delivery 7 (4) 208-222 [2015] 
 
 
  
PAGE | 221 | 
 
 
Table 13: Phytochemical Evaluation of Purified Gum Kondagogu 
S.No. Test Inference 
1. Water Solubility Test - 
2. Molisch Test ++ 
3. Fehlings TestTest ++ 
4. Solubility Test in Ethanol  - 
5. Iodine Test - 
                         ++ Present, - Negative 
 
 
Accelerated Stability Studies 
 
Stability studies of the optimized formulation did not reveal any 
degradation of the drug and dosage form. 
the values represented as mean ± Standard Deviation (SD), n=3.  
The stability of this optimized formulation was known by performing 
stability studies for three months at accelerated conditions of 400C 
+ 75 % RH on optimized formulation. The formulation was found to 
be stable, with no change in the weight variation, thickness, and 
friability, hardness, drug content and In vitro drug release pattern. 
The results are tabulated in table 11.  
 
Conclusion 
 
Finally the prolong release of valsartan from prepared matrix 
tablets was achieved by designing the formulations in such a way 
by varying proportions of polymer concentrations.    Among gum 
olibanum resin, purified gum kondagogu, locust bean gum the 
swelling index was higher for the tablets prepared by employing 
purified gum kondagogu. And it showed extent of swelling 3-4% of 
its original volume. 
Among all the batches of prepared matrix tablets, formulation 
prepared by employing the gum kondagugu in the concentration of 
30%, F8 showed better release of valsartan from matrix tablets of 
96.88 % and all the Pre-compression and Post-compression 
parameters are also within the limit as per pharmacopoeial 
standards.Further the analysis of release mechanism was carried 
out by fitting the drug release data to various kinetic equations like 
Zero order, First order, Higuchi’s and krosmeyer - peppas 
equations and from the values so obtained, the best fit model were 
arrived . 
Stability studies of the selected formulation was carried out to 
determine the effect of formulation additives on the stability of the 
drug and also to determine the physical stability of the formulation. 
The stability studies were carried out at 40°C/75% RH for 90days. 
There was no significant change in the physical property and 
weight variation, hardness, thickness, friability, swelling studies, 
surface pH, In vitro drug release studies, drug content during the 
study period. 
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